SEC Filing | Vaccinex, Inc.

View:

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

FRIEDBERG ALBERT

(Last)

(First)

(Middle)

220 BAY STREET

SUITE 600

(Street)

TORONTO

M5J 2W4

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VACCINEX, INC. [ VCNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Rule 10b5-1(c) Transaction Indication

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								2,094	D
Common Stock								180	I	By Pan Atlantic Holdings Ltd.⁽¹⁾
Common Stock								16,724	I	By Friedberg Global-Macro Hedge Fund Ltd.⁽²⁾
Common Stock	05/29/2024		P		957	A	$4.95	561,554	I	By FCMI Parent Co.⁽³⁾
Common Stock	05/30/2024		P		861	A	$5.195⁽⁴⁾	562,415	I	By FCMI Parent Co.⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrant (Right to Buy)	$7.64							03/28/2024	03/28/2029	Common Stock	102,960		102,960	I	By FCMI Parent Co.⁽³⁾
Warrant (Right to Buy)	$14							02/08/2024	02/08/2029	Common Stock	118,226		118,226	I	By FCMI Parent Co.⁽³⁾
Warrant (Right to Buy)	$14							10/03/2023	10/03/2028	Common Stock	214,285		214,285	I	By FCMI Parent Co.⁽³⁾

1. Name and Address of Reporting Person^*

FRIEDBERG ALBERT

(Last)

(First)

(Middle)

220 BAY STREET

SUITE 600

(Street)

TORONTO

M5J 2W4

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

FCMI Parent Co.

(Last)

(First)

(Middle)

220 BAY STREET

SUITE 600

(Street)

TORONTO

M5J 2W4

(City)

(State)

(Zip)

Explanation of Responses:

1. Mr. Friedberg is the majority owner of Pan Atlantic Holdings Ltd. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

2. Mr. Friedberg possesses voting and dispositive power over the reported securities and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

3. Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

4. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.17 to $5.20. The reporting persons undertake to provide Vaccinex, Inc., any security holder of Vaccinex, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Dan Scheiner, Attorney-in-Fact for Albert D. Friedberg	05/31/2024
	FCMI Parent Co. By: /s/ Dan Scheiner, Vice President	05/31/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Albert D. Friedberg
Limited Power of Attorney for Section 16 Reporting Obligations


Know all by these presents, that the undersigned hereby
constitutes and appoints Dan Scheiner as the
undersigned's true and lawful attorney-in-fact, with full
power of substitution and authority to:

(1) execute for and on behalf of the undersigned, in
the undersigned's capacity as an officer and/or director
of Vaccinex, Inc. (the "Company"), Forms 3, 4 and 5 in
accordance with Section 16(a) of the Securities Exchange
Act of 1934 and the rules thereunder, as amended from
time to time (the "Exchange Act");

(2) do and perform any and all acts for and on behalf of
the undersigned that may be necessary or desirable to
complete and execute any such Form 3, 4 or 5, including any
amendment or amendments thereto, and timely file such form
with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in
connection with the foregoing which, in the opinion of
such attorney-in-fact, may be of benefit to, in the best
interest of, or legally required by, the undersigned, it
being understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant to
this Limited Power of Attorney shall be in such form and
shall contain such information and disclosure as such
attorney-in-fact may approve in such attorney-in-fact's
discretion.

The undersigned hereby grants to each attorney-in-fact
full power and authority to do and perform any and every
act and thing whatsoever requisite, necessary or desirable
to be done in the exercise of any of the rights and powers
herein granted, as fully and to all intents and purposes
as the undersigned might or could do if personally present,
with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact,
or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Limited
Power of Attorney and the rights and powers herein granted.
The undersigned acknowledges that this Limited Power of
Attorney authorizes, but does not require each
attorney-in-fact to act in his discretion on information
provided to him without independent verification of such
information and further acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request
of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.

This Limited Power of Attorney shall remain in full
force and effect until July 31, 2024, at which time this
Limited Power of Attorney will become void, unless earlier
revoked by the undersigned in a signed writing to the foregoing
attorney in fact.

IN WITNESS WHEREOF, the undersigned has signed this Limited
Power of Attorney this 30th day of April 2024.


/s/ Albert D. Friedberg

Albert D. Friedberg